Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Mark Middleton

University of Oxford

United Kingdom

Has grant

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacology

10%

Immunology

40%

Cancer Biology

40%

Oncology

30%

Targeted Therapy

20%

Adjuvant Therapy

20%

Antiretroviral Therapy

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Recent Grants

Grant: Open

CRUK Oxford Centre

Open Date: 2022-04-01

Close Date: 2027-03-01

Grant: Close

Symplify Trial

Open Date: 2021-02-01

Close Date: 2024-03-01

Grant: Close

Permeabilisation of brain metastases for early and more effective treatment

Open Date: 2020-11-01

Close Date: 2024-12-31

Grant: Close

Permeabilisation of brain metastases for early detection and treatment

Open Date: 2016-06-30

Close Date: 2019-07-30

Grant: Close

Clinical Trial Research Fellowship

Open Date: 2015-06-01

Close Date: 2018-05-31

Articles10

Pseudotime dynamics of T cells in pancreatic ductal adenocarcinoma inform distinct functional states within the regulatory and cytotoxic T cells.

Article Link

Year:

2023

Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation.

Article Link

Year:

2023

Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology.

Article Link

Year:

2023

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

Article Link

Year:

2022

WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma.

Article Link

Year:

2022

IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.

Article Link

Year:

2022

A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.

Article Link

Year:

2022

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.

Article Link

Year:

2022

VCAM-1-targeted MRI Improves Detection of the Tumor-brain Interface.

Article Link

Year:

2022

Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies.

Article Link

Year:

2022

Collaborators12

Thierry André

Sorbonne Université

FRANCE

Orion Tong

UNITED KINGDOM

Lennard Lee

Associate Professor

University of Oxford

UNITED KINGDOM

James J Gilchrist

University of Oxford

UNITED KINGDOM

Rebecca S. Kristeleit

University of Arizona College of Medicine

UNITED STATES

Nicola R. Sibson

University of Oxford

UNITED KINGDOM

Matthew Fittall

Honorary Associate Professor

University College London

UNITED KINGDOM

Michael Dustin

Kennedy Trust Professor of Molecular Immunology

University of Oxford

UNITED KINGDOM

Pia Osterlund

Karolinska University Hospital

SWEDEN

Tim Robinson

University of Bristol

UNITED KINGDOM

Paul E. Van Schil

BELGIUM

Gary Middleton

Professor of Medical Oncology

University of Birmingham

UNITED KINGDOM

How do I reach out?

Meet Kite AI